Thursday September 17, 2020
17 Sep 2020 – Update on Phase 2b clinical study of lead asset XF-73 in the prevent...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections Recruitment on track to complete by […]
Thursday September 17, 2020
17 Sep 2020 – Interim results for the 6 months ended 30 June 2020
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2020, which can be found here.
Thursday September 10, 2020
10 Sep 2020 – Scrip article “Destiny Pharma and SporeGen back Nasal Spray ov...
To access Scrip article, please click on link below: Scrip “Destiny and SporeGen back Nasal Spray over Vaccine to tackle COVID-19”
Monday September 7, 2020